All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients

Cancer Research

Volumn 66, Issue 18, 2006, Pages 9299-9307

  Mirza, Noweeda ^a   Fishman, Mayer ^a   Fricke, Ingo ^a   Dunn, Mary ^a   Neuger, Anthony M ^a   Frost, Timothy J ^a   Lush, Richard M ^a   Antonia, Scott ^a   Gabrilovich, Dmitry I ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 2; RETINOIC ACID; TETANUS TOXOID;

ADULT; AGED; ARTICLE; BONE MARROW CELL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG EFFECT; DRUG POTENTIATION; DRY SKIN; FEMALE; HEADACHE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; KIDNEY CARCINOMA; MALE; MYALGIA; PRIORITY JOURNAL; T LYMPHOCYTE;

AGED; CARCINOMA, RENAL CELL; CELL DIFFERENTIATION; DENDRITIC CELLS; FEMALE; HUMANS; INTERLEUKIN-2; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; MYELOID CELLS; T-LYMPHOCYTES; TRETINOIN;

EID: 33749461167     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-1690     Document Type: Article

References (50)

1. Gabrilovich D, Pisarev V. Tumor escape from immune response: mechanisms and targets of activity. Curr Drug Targets 2003;4:525-36.
2. Gabrilovich D. The mechanisms and functional significance of tumour-induced dendritic-cell defects. Nat Rev Immunol 2004;4:941-52.
3. Subiza J, Vinuela J, Rodriguez R, De la Concha E. Development of splenic natural suppressor (NS) cells in Ehrlich tumor-bearing mice. Int J Cancer 1989;44:307-14.
4. + T cell responses by dysregulating antigen-presenting cell maturation. J Immunol 1999;162:5728-37.
5. + myeloid cells. J Immunol 2001;166:5398-406.
6. Melani C, Chiodoni C, Forni G, Colombo MP. Myeloid cell expansion elicited by the progression of spontaneous mammary carcinomas in c-erbB-2 transgenic BALB/c mice suppresses immune reactivity. Blood 2003;102:2138-45.
7. Almand B, Clark JI, Nikitina E, et al. Increased production of immature myeloid cells in cancer patients. A mechanism of immunosuppression in cancer. J Immunol 2001;166:678-89.
8. Bronte V, Serafini P, Appoloni E, Zanovello P. Tumor-induced immune dysfunctions caused by myeloid suppressor cells. J Immunother 2001;24:431-46.
9. Seung L, Rowley D, Dubeym P, Schreiber H. Synergy between T-cell immunity and inhibition of paracrine stimulation causes tumor rejection. Proc Natl Acad Sci U S A 1995;92:6254-8.
10. Terabe M, Matsui S, Park JM, et al. Transforming growth factor-β production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocyte-mediated tumor immunosurveillance: abrogation prevents tumor recurrence. J Exp Med 2003;198:1741-52.
11. Otsuji M, Kimura Y, Aoe T, Okamoto Y, Saito T. Oxidative stress by tumor-derived macrophages suppresses the expression of CD3ζ chain of T-cell receptor complex and antigen-specific T-cell responses. Proc Natl Acad Sci U S A 1996;93:13119-24.
12. + myeloid cells derived from tumor-bearing mice inhibit primary T cell activation induced through CD3/CD28 costimulation. J Immunol 2000;165:779-85.
13. Bronte V, Serafini P, De Santo C, et al. IL-4-induced arginase 1 suppresses alloreactive T cells in tumor-bearing mice. J Immunol 2003;170:270-8.
14. Liu Y, Van Ginderachter J, Brys L, De Baetselier P, Raes G, Geldhof A. Nitric oxide-independent CTL suppression during tumor progression: association with arginase-producing (M2) myeloid cells. J Immunol 2003;170:5064-74.
15. + T cell tolerance induced by bone marrow-derived immature myeloid cells. J Immunol 2005;175:4583-92.
16. Bronte V, Apolloni E, Cabrelle A, et al. Identification of a CD11b(+)/Gr-1(+)/CD31(+) myeloid progenitor capable of activating or suppressing CD8(+) T cells. Blood 2000;96:3838.
17. Kusmartsev S, Gabrilovich DI. Inhibition of myeloid cell differentiation in cancer: the role of reactive oxygen species. J Leukoc Biol 2003;74:186-96.
18. + cells in the development of antitumor immunity. Cancer Res 2004;64:1130-9.
19. Danna EA, Sinha P, Gilbert M, Clements VK, Pulaski BA, Ostrand-Rosenberg S. Surgical removal of primary tumor reverses tumor-induced immunosuppression despite the presence of metastatic disease. Cancer Res 2004;64:2205-11.
20. Almand B, Resser J, Lindman B, et al. Clinical significance of defective dendritic cell differentiation in cancer. Clin Cancer Res 2000;6:1755-66.
21. Schmielau J, Finn OJ. Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of T-cell function in advanced cancer patients. Cancer Res 2001;61:4756-60.
22. Hengesbach L, Hoag K. Physiological concentrations of retinoic acid favor myeloid dendritic cell development over granulocyte development in cultures of bone marrow cells from mice. J Nutr 2004;134:2653-9.
23. Kuwata T, Wang I, Tamura T, et al. Vitamin A deficiency in mice causes a systemic expansion of myeloid cells. Blood 2000;95:3349-56.
24. Walkley C, Yuan Y, Chandraratna R, McArthur G. Retinoic acid receptor antagonism in vivo expands the numbers of precursor cells during granulopoiesis. Leukemia 2002;16:1763-72.
25. Kusmartsev S, Cheng F, Yu B, et al. All-trans-retinoic acid eliminates immature myeloid cells from tumor-bearing mice and improves the effect of vaccination. Cancer Res 2003;63:4441-9.
26. Yang JC, Sherry RM, Steinberg SM, et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol 2003;21:3127-33.
27. Lanvers C, Reinhardt D, Dubbers A, et al. Pharmacology of all-trans-retinoic acid in children with acute promyelocytic leukemia. Med Pediatr Oncol 2003;40:293-301.
28. Muindi JR, Frankel SR, Huselton C, et al. Clinical pharmacology of oral all-trans retinoic acid in patients with acute promyelocytic leukemia. Cancer Res 1992;52:2138-42.
29. Wu C, Njar V, Brodie A, Borenstein M, Nnane I. Quantification of a novel retinoic acid metabolism inhibitor, 4-(1H-imidazol-1-yl)retinoic acid (VN/14-1RA) and other retinoids in rat plasma by liquid chromatography with diode-array detection. J Chromatogr B Analyt Technol Biomed Life Sci 2004;810:203-8.
30. Wang Y, Chang WY, Prins GS, van Breemen RB. Simultaneous determination of all-trans,9-cis,13-cis retinoic acid and retinol in rat prostate using liquid chromatography-mass spectrometry. J Mass Spectrom 2001;36:882-8.
31. Adamson PC. All-trans-retinoic acid pharmacology and its impact on the treatment of acute promyelocytic leukemia. Oncologist 1996;1:305-14.
32. Conley BA, Egorin MJ, Sridhara R, et al. Phase I clinical trial of all-trans-retinoic acid with correlation of its pharmacokinetics and pharmacodynamics. Cancer Chemother Pharmacol 1997;39:291-9.
33. Kusmartsev S, Gabrilovich DI. Role of immature myeloid cells in mechanisms of immune evasion in cancer. Cancer Immunol Immunother 2006;55:237-45.
34. Serafini P, Borrello I, Bronte V. Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression. Semin Cancer Biol 2006;16:53-65.
35. Dannull J, Kuebler HR, Tseng TT, et al. Immature myeloid cell (ImC)-mediated immunosuppression in advanced renal cell cancer (RCC). Proceedings of 97th Annual Meeting of American Association for Cancer Research, Washington, 2006; Abstract no. 3866.
36. Hittelman WN, Agbor P, Petkovic I, et al. Detection of lekemic clone maturation in vivo by premature chromosome condensation. Blood 1988;72:1950-60.
37. + BM cells. Ann Hematol 1993;66:61-6.
38. Tohda S, Minden MD. Modulation of growth factor receptors on acute myeloblastic leukemia cells by retinoic acid. Jpn J Cancer Res 1994;85:378-83.
39. Castaigne S, Chomienne C, Daniel MT, et al. All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. I. Clinical results. Blood 1990;76:1704-9.
40. Warrell RP, Frankel SR, Miller WH, et al. Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). N Engl J Med 1991;324:1385-93.
41. Bastien J, Rochette-Egly C. Nuclear retinoid receptors and the transcription of retinoid-target genes. Gene 2004;328:1-16.
42. Xu X, Wong W, Goldberg L, et al. Progressive decreases in nuclear retinoid receptors during skin squamous carcinogenesis. Cancer Res 2001;61:4306-10.
43. Chen GQ, Shen ZX, Wu F, et al. Pharmacokinetics and efficacy of low-dose all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Leukemia 1996;10:825-8.
44. Arpinati M, Chirumbolo G, Urbini B, Perrone G, Rondelli D, Anasetti C. Role of plasmacytoid dendritic cells in immunity and tolerance after allogeneic hematopoietic stem cell transplantation. Transpl Immunol 2003;11:345-56.
45. Zou W, Machelon V, Coulomb-L'Hermin A, et al. Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells. Nat Med 2001;7:1339-46.
46. Treilleux I, Blay JY, Bendriss-Vermare N, et al. Dendritic cell infiltration and prognosis of early stage breast cancer. Clin Cancer Res 2004;10:7466-74.
47. Bella SD, Gennaro M, Vaccari M, et al. Altered maturation of peripheral blood dendritic cells in patients with breast cancer. Br J Cancer 2003;89:1463-72.
48. Hoffmann TK, Muller-Berghaus J, Ferris RL, Johnson JT, Storkus WJ, Whiteside TL. Alterations in the frequency of dendritic cell subsets in the peripheral circulation of patients with squamous cell carcinomas of the head and neck. Clin Cancer Res 2002;8:1787-93.
49. Khatri VP, Baiocchi RA, Bernstein ZP, Caligiuri MA. Immunotherapy with low-dose interleukin-2: rationale for prevention of immune-deficiency-associated cancer. Cancer J Sci Am 1997;3 Suppl 1:S129-36.
50. Sosman JA, Hank JA, Moore KH, et al. Prolonged interleukin-2 (IL-2) treatment can augment immune activation without enhancing antitumor activity in renal cell carcinoma. Cancer Invest 1991;9:35-48.